
GenapSys
Total Raised
$283.2MInvestors Count
16Deal Terms
3Funding, Valuation & Revenue
12 Fundings
GenapSys has raised $283.2M over 12 rounds.
GenapSys's latest funding round was a Asset Sale for on September 8, 2022.
GenapSys's latest post-money valuation is from September 2022.
Sign up for a free demo to see GenapSys's valuations in September 2022 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
9/8/2022 | Asset Sale | 2 | ||||
5/27/2021 | Series D - II | $41.5M | 1 | |||
3/4/2021 | Series D | $28.5M | Nazem & Company, Prologis Ventures, and Undisclosed Investors | 2 | ||
4/10/2020 | Loan | |||||
2/6/2020 | Series C - II |
Date | 9/8/2022 | 5/27/2021 | 3/4/2021 | 4/10/2020 | 2/6/2020 |
|---|---|---|---|---|---|
Round | Asset Sale | Series D - II | Series D | Loan | Series C - II |
Amount | $41.5M | $28.5M | |||
Investors | Nazem & Company, Prologis Ventures, and Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 2 | 1 | 2 |
GenapSys Deal Terms
3 Deal Terms
GenapSys's deal structure is available for 3 funding rounds, including their Asset Sale from September 08, 2022.
Round | Asset Sale | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Asset Sale | |||||||||||||||
Series B | |||||||||||||||
Series A |
GenapSys Investors
16 Investors
GenapSys has 16 investors. Sequence Health invested in GenapSys's Asset Sale funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/8/2022 | 9/8/2022 | 1 Asset Sale | Academic/University | Georgia | ||
5/27/2021 | 5/27/2021 | 1 Series D - II | Asset/Investment Management | California | ||
5/27/2021 | 5/27/2021 | 1 Series D - II | Private Equity | Connecticut | ||
Corporate Venture | California | |||||
Hedge Fund | New York |
First funding | 9/8/2022 | 5/27/2021 | 5/27/2021 | ||
|---|---|---|---|---|---|
Last Funding | 9/8/2022 | 5/27/2021 | 5/27/2021 | ||
Investor | |||||
Rounds | 1 Asset Sale | 1 Series D - II | 1 Series D - II | ||
Board Seats | |||||
Type | Academic/University | Asset/Investment Management | Private Equity | Corporate Venture | Hedge Fund |
Location | Georgia | California | Connecticut | California | New York |
Compare GenapSys to Competitors

PerkinElmer operates as a provider of technology and service solutions in the laboratory sector, focusing on food, industrial, life sciences, and environmental markets. The company offers a range of products and services, including laboratory technologies for analysis and characterization, atomic spectroscopy, chromatography, and food quality analyzers. PerkinElmer's solutions help customers evaluate the quality and safety of products. It was founded in 1937 and is based in Shelton, Connecticut.
Algorithmic Biologics provides molecular computing solutions for diagnostics and research in the life sciences industry. The company offers cloud-delivered services that improve the processes of PCR, NGS, mass spectrometry, assay design, and drug discovery. Algorithmic Biologics serves sectors that require molecular analysis and diagnostics, including healthcare and pharmaceutical research. It was founded in 2021 and is based in Bengaluru, India.

American Biosystems produces enzymes and direct-fed microbials for sectors within the agriculture and wastewater treatment industries. Their product offerings include fermentation products and enzyme blends aimed at animal nutrition, aquaculture systems, and municipal and industrial wastewater treatment processes. The company serves the aquaculture industry, wastewater treatment facilities, and the agricultural sector with animal feed additives. It is based in Roanoke, Virginia.

Cellectis is a clinical-stage biotechnology company specializing in gene editing within the biopharmaceutical sector, focusing on developing treatments for cancer through its TALEN technology. The company offers a gene editing platform that enables the creation of allogeneic CAR-T cells, with a primary focus on immuno-oncology and gene therapy. Cellectis is involved in the process of gene and cell therapy, from manufacturing to product development, and collaborates with various companies to advance treatments in oncology, immunology, and rare diseases. It was founded in 1999 and is based in Paris, France.

PTC Therapeutics is a biopharmaceutical company involved in the research and development of medicines for children and adults with diseases that have significant unmet medical needs. The company develops therapies for rare diseases, including splicing modifiers and treatments for conditions like Duchenne muscular dystrophy and Friedreich's ataxia. PTC Therapeutics serves the healthcare sector, providing treatment options and assistance for patients and healthcare providers. It was founded in 1998 and is based in South Plainfield, New Jersey.

Sartorius focuses in life sciences research and biopharmaceutical manufacturing, providing laboratory instruments and consumables. The company supplies solutions for drug discovery, development, and production platforms for biomanufacturing, with an emphasis on single-use products for bioprocessing. Sartorius serves pharmaceutical and biopharmaceutical companies, as well as academic research institutions. It was founded in 1870 and is based in Goettingen, Germany.
Loading...

